Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
NCT00686036 · Genzyme, a Sanofi Company · PHASE2 · terminated · last registry update 2016-12-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow recruitment” | – | Registry record, Genzyme, a Sanofi Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SRC within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-05-17Results posted on the registry: National Cancer Institute (NCI), Bortezomib + Vandetanib (NCT00923247)
- 2017-04-24Also stopped (withdrawn): SWOG Cancer Research Network, docetaxel + vandetanib (NCT00937417)
- 2017-04-10Phase 3 first posted: Novartis Pharmaceuticals, Asciminib + Bosutinib (NCT03106779)
- 2017-03-13Results posted on the registry: Genzyme, a Sanofi Company, Vandetanib (SAR390530) + Placebo (NCT01876784)
- 2017-02-07Results posted on the registry: Stanford University, Vandetanib + Anastrozole (NCT00481845)
- 2017-02-07Also stopped (terminated): Stanford University, Vandetanib + Anastrozole (NCT00481845)
- 2016-12-19Results posted on the registry: SWOG Cancer Research Network, docetaxel + vandetanib (NCT00872989)
- 2016-12-05Also stopped (terminated): Genzyme, a Sanofi Company, ZD6474 (Vandetanib at the dose of 100 mg) + Placebo to match ZD6474 (Vandetanib at the dose of 100 mg) (NCT00752986)
- 2016-10-10Also stopped (terminated): Genzyme, a Sanofi Company, Vinorelbine + Vandetanib (NCT00597116)
- 2016-10-10Also stopped (terminated): Genzyme, a Sanofi Company, Vandetanib (NCT00862836)
- 2016-08-29Also stopped (terminated): Sanofi, ZD6474 (Vandetanib) + ZD6474 (NCT00807170)
- 2016-06-20Results posted on the registry: Massachusetts General Hospital, bosutinib (NCT01331291)
- 2016-05-19Also stopped (terminated): M.D. Anderson Cancer Center, ZD6474 + Carboplatin (NCT00290537)
- 2016-03-29Results posted on the registry: National Cancer Institute (NCI), ZD6474 (Vandetanib) + Carboplatin (NCT00995007)
- 2016-03-09Results posted on the registry: M.D. Anderson Cancer Center, ZD6474 (NCT00402896)
- 2016-03-09Also stopped (terminated): M.D. Anderson Cancer Center, ZD6474 (NCT00402896)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision